Fig. 15From: Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysisMeta-analysis of diarrhea. ALTTOa: trastuzumab followed by lapatinib groupBack to article page